Bioventus Inc (BVS)vsEdwards Lifesciences Corp (EW)
BVS
Bioventus Inc
$9.15
+1.67%
HEALTHCARE · Cap: $582.06M
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 968% more annual revenue ($6.07B vs $568.09M). EW leads profitability with a 17.7% profit margin vs 4.0%. BVS appears more attractively valued with a PEG of 1.15. EW earns a higher WallStSmart Score of 55/100 (C).
BVS
Hold49
out of 100
Grade: D+
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-260.7%
Fair Value
$2.24
Current Price
$9.15
$6.91 premium
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Strong operational efficiency at 23.7%
Areas to Watch
Moderate valuation
2.8% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : BVS
PEG of 1.15 suggests the stock is reasonably priced for its growth.
Bull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bear Case : BVS
The primary concerns for BVS are P/E Ratio, Revenue Growth, EPS Growth. Thin 4.0% margins leave little buffer for downturns.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Key Dynamics to Monitor
BVS profiles as a value stock while EW is a mature play — different risk/reward profiles.
EW carries more volatility with a beta of 0.93 — expect wider price swings.
EW is growing revenue faster at 13.3% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 49/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bioventus Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?